Product Description
Calcium acetate is used to treat hyperphosphatemia (too much phosphate in the blood) in patients with end stage kidney disease who are on dialysis. Calcium acetate works by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed. (Sourced from: https://www.mayoclinic.org/drugs-supplements/calcium-acetate-oral-route/proper-use/drg-20062494?p=1)
Mechanisms of Action: Phosphate Binder
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Austria | Bangladesh | Belgium | Canada | Chile | Croatia | Dominican Republic | Egypt | France | Germany | Greece | India | Italy | Korea | Mexico | Morocco | New Zealand | Pakistan | Russia | South Africa | Spain | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Fresenius
Company Location: BAD HOMBURG 2M 61352
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Anemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20230498 | P1 |
Active, not recruiting |
Anemia |
None |